Prospects of immune checkpoint modulators in the treatment of glioblastoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Authors
Keywords
-
Journal
Nature Reviews Neurology
Volume 11, Issue 9, Pages 504-514
Publisher
Springer Nature
Online
2015-08-11
DOI
10.1038/nrneurol.2015.139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for glioma immunotherapy: the next generation
- (2015) Jennifer S. Sims et al. JOURNAL OF NEURO-ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: Table 1.
- (2015) Gordana Vlahovic et al. NEURO-ONCOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- (2015) Jason J. Luke et al. Oncotarget
- Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
- (2014) S Han et al. BRITISH JOURNAL OF CANCER
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- The role of regulatory T-cells in glioma immunology
- (2014) Yinn Cher Ooi et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
- (2014) Anna Sophie Berghoff et al. HISTOPATHOLOGY
- The Effect of Radiation on the Immune Response to Cancers
- (2014) Bonggoo Park et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
- (2014) Michael Weller et al. LANCET ONCOLOGY
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- A step towards clinical blood biomarkers of glioblastoma
- (2014) Matthias Preusser Nature Reviews Neurology
- Immunotherapy advances for glioblastoma
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
- (2014) Q. T. Ostrom et al. NEURO-ONCOLOGY
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
- (2014) Zineb Belcaid et al. PLoS One
- Hematogenous dissemination of glioblastoma multiforme
- (2014) C. Muller et al. Science Translational Medicine
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
- (2014) Antonio M Grimaldi et al. OncoImmunology
- Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
- (2014) Mizuki Nishino et al. Journal for ImmunoTherapy of Cancer
- Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
- (2013) Krishna P.L. Bhat et al. CANCER CELL
- Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class
- (2013) W. C. Rutledge et al. CLINICAL CANCER RESEARCH
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
- (2013) O. Bloch et al. CLINICAL CANCER RESEARCH
- PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
- (2013) Anna Sophie Berghoff et al. CLINICAL NEUROPATHOLOGY
- Myeloid-derived suppressor cells in glioma
- (2013) Masoud Mirghorbani et al. Expert Review of Neurotherapeutics
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma
- (2013) Qi Yue et al. JOURNAL OF NEURO-ONCOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology
- (2013) Glenn Dranoff NATURE MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
- (2013) Luis A. Sanchez-Perez et al. PLoS One
- Targeting Brain Metastases in Patients with Melanoma
- (2013) Dionysis Papadatos-Pastos et al. Biomed Research International
- Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
- (2013) T. Doucette et al. Cancer Immunology Research
- The nature of activatory and tolerogenic dendritic cell-derived signal II
- (2013) Ghaith Bakdash et al. Frontiers in Immunology
- The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
- (2013) Aaron S. Mansfield et al. OncoImmunology
- How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
- (2012) J. Wolchok ANNALS OF ONCOLOGY
- Modulation of Immunity by Antiangiogenic Molecules in Cancer
- (2012) Magali Terme et al. Clinical & Developmental Immunology
- Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
- (2012) B. Frey et al. CURRENT MEDICINAL CHEMISTRY
- MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
- (2012) A. Juszczak et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
- (2011) Christopher Jackson et al. Clinical & Developmental Immunology
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
- (2011) Stuart A. Grossman et al. CLINICAL CANCER RESEARCH
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
- (2011) N. Joller et al. JOURNAL OF IMMUNOLOGY
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
- (2010) Le Min et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The CD4-like molecule LAG-3, biology and therapeutic applications
- (2010) Sophie Sierro et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
- (2010) Roger Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions
- (2010) Tony Avril et al. JOURNAL OF NEUROIMMUNOLOGY
- Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?
- (2010) A. B. Heimberger et al. NEURO-ONCOLOGY
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Issues in Developing Drugs for Primary Brain Tumors: Barriers and Toxicities
- (2010) Jeffrey Raizer TOXICOLOGIC PATHOLOGY
- CTLA-4 blockade: therapeutic potential in cancer treatments
- (2010) Ahmad Tarhini OncoTargets and Therapy
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
- (2009) William D. Hastings et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Costimulatory and coinhibitory receptors in anti-tumor immunity
- (2009) Gregory Driessens et al. IMMUNOLOGICAL REVIEWS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- The anticancer immune response: indispensable for therapeutic success?
- (2008) Laurence Zitvogel et al. JOURNAL OF CLINICAL INVESTIGATION
- TIMs: central regulators of immune responses: Figure 1.
- (2008) David A. Hafler et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now